1. Home
  2. PD vs AKRO Comparison

PD vs AKRO Comparison

Compare PD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PD
  • AKRO
  • Stock Information
  • Founded
  • PD 2009
  • AKRO 2017
  • Country
  • PD United States
  • AKRO United States
  • Employees
  • PD N/A
  • AKRO N/A
  • Industry
  • PD Computer Software: Prepackaged Software
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PD Technology
  • AKRO Health Care
  • Exchange
  • PD Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • PD 1.4B
  • AKRO 3.9B
  • IPO Year
  • PD 2019
  • AKRO 2019
  • Fundamental
  • Price
  • PD $15.99
  • AKRO $51.77
  • Analyst Decision
  • PD Buy
  • AKRO Strong Buy
  • Analyst Count
  • PD 12
  • AKRO 6
  • Target Price
  • PD $19.50
  • AKRO $82.50
  • AVG Volume (30 Days)
  • PD 1.6M
  • AKRO 1.7M
  • Earning Date
  • PD 09-02-2025
  • AKRO 08-08-2025
  • Dividend Yield
  • PD N/A
  • AKRO N/A
  • EPS Growth
  • PD N/A
  • AKRO N/A
  • EPS
  • PD N/A
  • AKRO N/A
  • Revenue
  • PD $476,132,000.00
  • AKRO N/A
  • Revenue This Year
  • PD $9.60
  • AKRO N/A
  • Revenue Next Year
  • PD $7.56
  • AKRO N/A
  • P/E Ratio
  • PD N/A
  • AKRO N/A
  • Revenue Growth
  • PD 8.55
  • AKRO N/A
  • 52 Week Low
  • PD $13.70
  • AKRO $21.02
  • 52 Week High
  • PD $22.51
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • PD 59.65
  • AKRO 49.14
  • Support Level
  • PD $15.09
  • AKRO $51.08
  • Resistance Level
  • PD $16.49
  • AKRO $57.35
  • Average True Range (ATR)
  • PD 0.46
  • AKRO 2.21
  • MACD
  • PD 0.20
  • AKRO -0.81
  • Stochastic Oscillator
  • PD 94.64
  • AKRO 11.08

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: